We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+8.32%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$395M
AUM Growth
-$62.2M
Cap. Flow
-$70.5M
Cap. Flow %
-17.83%
Top 10 Hldgs %
40.77%
Holding
93
New
11
Increased
18
Reduced
29
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$8.57M
2
IMUX icon
Immunic
IMUX
+$5.02M
3
AMGN icon
Amgen
AMGN
+$4.6M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$4.28M
5
FULC icon
Fulcrum Therapeutics
FULC
+$3.65M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$18M
2
CRL icon
Charles River Laboratories
CRL
+$11.3M
3
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
+$7.96M
4
XLRN
Acceleron Pharma
XLRN
+$7.54M
5
NVRO
NEVRO CORP.
NVRO
+$5.93M

Sector Composition

Rank Sector Weight
1 Healthcare 97.83%
2 Industrials 0.81%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$6.31B
$4.75M 1.2%
311,207
-90,000
-22% -$1.56M
XRAY icon
27
Dentsply Sirona
XRAY
$2.27B
$4.67M 1.18%
80,455
-30,000
-27% -$1.85M
IONS icon
28
Ionis Pharmaceuticals
IONS
$9.39B
$4.57M 1.16%
136,380
– –
MRVI icon
29
Maravai LifeSciences
MRVI
$861M
$4.42M 1.12%
90,000
– –
AMGN icon
30
Amgen
AMGN
$225B
$4.25M 1.08%
+20,000
New +$4.6M
DRNA
31
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$4.23M 1.07%
209,686
-95,000
-31% -$2.62M
AZTA icon
32
Azenta
AZTA
$1.47B
$4.09M 1.04%
+40,000
New +$3.58M
PHLT
33
DELISTED
Performant Healthcare Inc
PHLT
$3.87M 0.98%
977,334
+480,000
+97% +$2.12M
KOD icon
34
Kodiak Sciences
KOD
$2.72B
$3.52M 0.89%
36,702
– –
HBIO icon
35
Harvard Bioscience
HBIO
$27.8M
$3.32M 0.84%
47,537
+7,300
+18% +$581K
RCM
36
DELISTED
R1 RCM Inc. Common Stock
RCM
$3.19M 0.81%
+145,000
New +$3M
AXGN icon
37
Axogen
AXGN
$2.67B
$3.16M 0.8%
200,000
-37,652
-16% -$676K
SMLR
38
DELISTED
Semler Scientific
SMLR
$3.13M 0.79%
+24,998
New +$3.16M
STRO icon
39
Sutro Biopharma
STRO
$353M
$3.09M 0.78%
16,339
– –
ATEC icon
40
Alphatec Holdings
ATEC
$1.49B
$3.05M 0.77%
+250,000
New +$3.49M
BCYC
41
Bicycle Therapeutics
BCYC
$284M
$2.89M 0.73%
69,549
-11,290
-14% -$395K
ETNB
42
DELISTED
89bio
ETNB
$2.86M 0.72%
145,848
+10,000
+7% +$183K
NOTV
43
DELISTED
Inotiv
NOTV
$2.85M 0.72%
97,500
-17,500
-15% -$509K
ANIP icon
44
ANI Pharmaceuticals
ANIP
$1.73B
$2.8M 0.71%
85,346
+30,000
+54% +$933K
BBIO icon
45
BridgeBio Pharma
BBIO
$16.4B
$2.72M 0.69%
57,978
– –
SUPN icon
46
Supernus Pharmaceuticals
SUPN
$2.78B
$2.68M 0.68%
100,415
– –
SIEN
47
DELISTED
Sientra, Inc.
SIEN
$2.53M 0.64%
44,175
+14,000
+46% +$956K
HCAT icon
48
Health Catalyst
HCAT
$135M
$2.53M 0.64%
50,515
– –
MDGL icon
49
Madrigal Pharmaceuticals
MDGL
$12.4B
$2.5M 0.63%
31,393
-5,000
-14% -$432K
OM icon
50
Outset Medical
OM
$84.6M
$2.49M 0.63%
3,356
-1,333
-28% -$908K
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Parkman Healthcare Partners held 93 positions worth $395M, down 14% from $457M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Parkman Healthcare Partners withdrew a net $70.5M in Q3 2021, closing 19 positions and reducing 29 holdings. Its most notable exit was Intuitive Surgical, an estimated $18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

Against the trend, Parkman Healthcare Partners opened a new position in AbbVie worth $8.09M.

  • Parkman Healthcare Partners's largest Q3 2021 buy was AbbVie: 75,000 shares worth $8.09M.
  • Parkman Healthcare Partners added most to Immunic in Q3 2021, an estimated $5.02M increase.
  • Parkman Healthcare Partners's biggest Q3 2021 reduction was Charles River Laboratories, cutting an estimated $11.3M.
  • Parkman Healthcare Partners fully exited Intuitive Surgical in Q3 2021, selling an estimated $18M.
  • Parkman Healthcare Partners's ten largest holdings make up 41% of its $395M portfolio in Q3 2021.
  • Parkman Healthcare Partners opened 11 new positions and closed 19 in Q3 2021.
  • Parkman Healthcare Partners's portfolio value fell 14% quarter-over-quarter to $395M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.